

AHCC Trials Group

Newsletter Jan 2015

The Buzz

The AHCC Trials Group wishes everyone a
Happy New Year.



Contents

Page 1

The Buzz

- Season Greetings

Page 2-4

Happenings

- AHCC Trials Group
Scientific Forum and
General Meeting,
31 October 2014

Page 5

Highlights

- AHCC06 Study Status

AHCC Trials Group

Group Chair:

Prof Soo Khee Chee

Protocol Chair, AHCC06:

Prof Pierce Chow

Trials Group Website:

[http://www.scri.edu.sg/
index.php/ahcc-trials-group](http://www.scri.edu.sg/index.php/ahcc-trials-group)

Trial Coordinating Centre:

Season Greetings to all members of the AHCC Trials Group!

The New Year is here and the AHCC Trials Group wants to take this opportunity to extend our heartfelt greetings for the season and appreciation to all investigators, study team members, collaborators and sponsors for their contribution, support and dedication for last year.

2014 has been an exciting and fruitful year with the AHCC 06 reaching its last leg of recruitment and successfully completed its 2nd interim analysis. The Trials Group has held its 6th General Meeting and its 1st Scientific Forum in October 2014 and it is now in a collaborative partnership with pharmaceutical companies.

Going forward in 2015, we will be expecting a few important milestones. The AHCC06 trial will be expected to complete recruitment and have its final analysis. Our investigators are currently conducting preliminary studies and designing the next clinical trial. We also look forward to having more members and collaborations with the industry.

Once again, we thank you all for your support and hope this relationship continues and we achieve success together.

AHCC Trials Group Scientific Forum and General Meeting 31 October 2014, Singapore

AHCC Trials Group Scientific Forum

The Asia Pacific Hepatocellular Carcinoma (AHCC) Trials Group held its first ever Scientific Forum at National Cancer Centre Singapore on 31st October 2014. This forum was open to the general public and more than 90 participants from 12 countries took part in this event. There was a good line-up of scientific and clinical speakers who shared their extensive research and clinical experience with HCC.

The Director of the National Cancer Centre Singapore and the Group Chair of the AHCC Trials Group, Professor Soo Khee Chee, gave his welcome address followed by a short introduction to the AHCC Trials Group by the Protocol Chair of the AHCC Trials Group, Professor Pierce Chow. Dr Zhai Wei Wei, Senior Research Scientist at the Genome Institute of Singapore, shared about using evolutionary and population genetic approaches in HCC. Professor Sven Pettersson from Lee Kong Chian School of Medicine, Nanyang Technological University, presented on the human microbiome and HCC while Associate Professor Ken Sung Wing Kin from the National University of Singapore and Genome Institute of Singapore spoke about the relevance of Hepatitis B genotype in HCC.

Clinical speakers that took part in the scientific program were Professor Simone Strasser from Royal Prince Alfred Hospital, Australia and Professor Khin Maung Win from Yangon GI and Liver Centre, Myanmar. Professor Strasser shared about her extensive clinical experience in treating HCC in Australia and Professor Khin Maung Win presented on the challenges faced in managing HCC in Myanmar.

In addition, we also had invited speakers from pharmaceutical companies. Dr Jennifer Yang, Director of Oncology Research from Johnson & Johnson China R&D, spoke on "Targeting FGFR Pathway for HCC". Dr Winston Lee, Regional Medical Director Asia Pacific for Sirtex Medical, gave a presentation on using Yttrium-90 in HCC.

The scientific forum ended with a lunch reception for all participants.



(Left) Prof Soo Khee Chee (Director, NCCS) gave his welcome address at the Scientific Forum.


(Right) Doctors from Myanmar, Prof Khin Maung Win (Yangon GI and Liver Centre, Myanmar) and Mr Xia Yu (Project Manager for AHCC06, SCRI) at the Scientific Forum

AHCC Trials Group Scientific Forum Poster

Asia-Pacific
Hepatocellular Carcinoma
Trials Group

ASIA-PACIFIC HEPATOCELLULAR CARCINOMA (AHCC) TRIALS GROUP SCIENTIFIC FORUM

The scientific forum will feature leading speakers from the Asia-Pacific region who will share their scientific experiences in Hepatocellular Carcinoma (HCC).



Dr Zhai Wei Wei
Senior Researcher Scientist
Genome Institute of
Singapore



Prof Sven Pettersson
Lee Kong Chian School of
Medicine, Singapore



Prof Ken Sung Wing Kin
Senior Group Leader
Genome Institute of
Singapore



Prof Simone Strasser
Royal Prince Alfred
Hospital, Australia



Prof Khin Maung Win
Yangon GI & Liver Centre,
Myanmar



Dr Jennifer Yang
Director of Oncology
Research
Johnson & Johnson China
R&D



Dr Gregory Lee
Medical Director
Global, Strix

Date: 31 October 2014, Friday
Time: 8:30am - 11:30am
Venue: National Cancer Centre Singapore
Peter and Mary Fu Auditorium, Level 4
11 Hospital Drive Singapore 169608

For registration, please email ahcctrialsgroup@nccs.com.sg

*Lunch will be provided for all registered participants



AHCC Trials Group General Meeting

The AHCC Trials Group also achieved another milestone by organizing its 6th General Meeting on 31st October 2014 at Duke-NUS Graduate Medical School Singapore. The General Meeting commenced after the AHCC Trials Group Scientific Forum and more than 25 participants from Australia, Indonesia, Malaysia, Myanmar, Mongolia, Philippines, South Korea, Singapore and Taiwan took part in this event. The meeting was attended by both AHCC06 Investigators and other members of the AHCC Trials Group.

During the meeting, Professor Pierce Chow updated the group on the AHCC06 (Sirvenib) Trial and the key outcomes of the 2nd Interim Analysis of the trial that was held on 27th October 2014. Professor Chow also shared on the recommendations from the Data Monitoring Committee in regards to the 2nd Interim Analysis.

Several ongoing pilot studies on HCC were also presented at the meeting. Dr Teo Jin Yao from Singapore General Hospital talked about an ongoing pilot study on hypertrophy of the contralateral lobe after SIRT. Professor Pierce Chow also presented on two pilot studies with the Genome Institute of Singapore on HCC tumor heterogeneity and HBV genotypes in HCC. An exploratory study on the microbiome and HCC conducted by both National Cancer Centre Singapore and Nanyang Technological University was also presented during the meeting. The General Meeting concluded with a dinner reception with all the AHCC Trials Group members followed by a Night Bus Tour of Singapore.

Overall, the first AHCC Trials Group Scientific Forum and General Meeting was a stimulating learning and sharing experience for scientific and clinical participants alike. The study team would like to thank the Investigators, AHCC Trials Group Members, distinguished speakers and sponsors for making this event a success.



6th AHCC Trials Group General Meeting held at Duke-NUS Graduate Medical School.

AHCC06 (SIRveNIB)

Phase III Multi-Centre Open-Label Randomized Control Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma

Protocol Chair: Prof Pierce Chow, NCCS, SGH and Duke-NUS

Study Status

As of 31st December 2014, 281 patients have been randomized. This is 78% of the target enrolment and 9 patients were randomised in December.

From the investigators meetings held in 2012 and 2014, most sites have suggested refresher courses for the study team members on site. Protocol Chair, Professor Pierce Chow and the team of CRAs have looked into this and they have been conducting refresher courses for both overseas and local sites since last year. At the same time, the sites are beginning to benefit from the additional funding of SGD 1.9 million from Sirtex which enable patients to follow up after treatment. These supports aim at improving the quality of the data and increasing the rate of recruitment. Response to these supports has been good and the recruitment has been increasing steadily.

2 sites are in the process of joining the trial, namely University Malaya Medical Centre (UMMC), Malaysia and National Cheng Kung University Hospital (NCKUH), Taiwan. The Site Initiation Visit at UMMC is planned in January 2014.

We welcome UMMC and NCKUH to the AHCC06 trial and thank the sites for their hard work and support.



6th AHCC Trials Group General Meeting

For more details on the AHCC06 trial, please visit <http://www.sirvenib.com/>

Participating Centres:

Brunei

- The Brunei Cancer Centre

Hong Kong

- Queen Mary Hospital

Indonesia

- University of Indonesia
- Sanglah General Hospital

Korea

- Asan Medical Center
- Korea Anam University Hospital
- Seoul National University Bundang Hospital
- Seoul St. Mary's Hospital
- Severance Hospital

Malaysia

- Penang Adventist Hospital

Mongolia

- National Cancer Center

Myanmar

- Yangon GI & Liver Centre

New Zealand

- Auckland City Hospital

Philippines

- Makati Medical Center
- St. Luke's Medical Center
- The Medical City
- Davao Doctors Hospital

Singapore

- Khoo Teck Puat Hospital
- National Cancer Centre
- National University Hospital
- Singapore General Hospital

Taiwan

- National Taiwan University Hospital
- Chang Gung Memorial Hospital, LK
- Taipei Veterans General Hospital
- China Medical University Hospital

Thailand

- Chulabhorn Hospital

Investigators in Town



The investigators were invited to enjoy a city night tour of Singapore after the 6th AHCC Trials Group General Meeting. We look forward to the next General Meeting in May 2015.

Contact Details

For further queries, please contact the AHCC Trials Group at

Project Manager (AHCC06):

Mr Xia Yu

Email: yu.xia@scri.edu.sg

DID: (65) 6508 8314

Network Secretariat:

Ms Lynette Lai

Email: lynette.lai.s.h@sqh.com.sg / ahcctrialsgroup@nccs.com.sg

DID: (65) 6326 2151

Ms Phang Su Ting

Email: phang.su.ting@sqh.com.sg

DID: (65) 6576 6450

Ms Rachel Choi

Email: rachel.choi.h.y@sqh.com.sg

DID: (65) 6576 7657

Read more about all trials
under AHCC Trials Group at
<http://www.scri.edu.sg>.

Mailing Address: 31 Biopolis Way Nanos #02-01 Singapore 138669

Acknowledgements: National Medical Research Council Singapore, SingHealth Foundation, PsiOncology, Sirtex Medical and Bayer Pharmaceutical for support of our clinical trials, past and present.